Cutting Edge: FcγRIII (CD16) and FcγRI (CD64) Are Responsible for Anti-Glycoprotein 75 Monoclonal Antibody TA99 Therapy for Experimental Metastatic B16 Melanoma
| Autor: | Pierre Bruhns, Andrew J. Murphy, Marcello Albanesi, Laurence Zitvogel, Jeanette H. W. Leusen, Bruno Iannascoli, David A. Mancardi, Macdonald Lynn |
|---|---|
| Přispěvatelé: | Anticorps en Thérapie et Pathologie, Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Allergologie Moléculaire et Cellulaire, Regeneron Pharmaceuticals [Tarrytown], Immunologie des tumeurs et immunothérapie (UMR 1015), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Gustave Roussy (IGR)-Université Paris-Sud - Paris 11 (UP11), University Medical Center [Utrecht], This work was supported by the Institut Pasteur, the INSERM, the Agence Nationale de la Recherche (Grant 09-GENO-014-01), the Fondation Association pour la Recherche sur le Cancer, and the Ligue Nationale contre le Cancer (Comité de Paris). M.A. is a scholar from the Pasteur Paris University International Doctoral Program., ANR-09-GENO-0014,InflammAbs,Contrôle de l'inflammation par les RFc humains dans des modèles murins d'allergie et d'autoimmunité.(2009), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM) |
| Rok vydání: | 2012 |
| Předmět: |
Lung Neoplasms
Cyclophosphamide Combination therapy medicine.drug_class MESH: Hybridomas Immunology Melanoma Experimental MESH: Receptors IgG CD16 Monoclonal antibody MESH: Mice Knockout MESH: Antibodies Monoclonal Mice Viral Proteins 03 medical and health sciences 0302 clinical medicine MESH: Mice Inbred C57BL MESH: Arboviruses MESH: Antibodies Blocking medicine Animals Immunology and Allergy MESH: Animals Antibodies Blocking MESH: Mice 030304 developmental biology Mice Knockout CD64 chemistry.chemical_classification 0303 health sciences Hybridomas business.industry Receptors IgG Antibodies Monoclonal MESH: Viral Proteins MESH: Lung Neoplasms 3. Good health Mice Inbred C57BL MESH: Melanoma Experimental chemistry Tumor reduction [SDV.IMM]Life Sciences [q-bio]/Immunology Glycoprotein business Arboviruses B16 melanoma 030215 immunology medicine.drug |
| Zdroj: | Journal of Immunology Journal of Immunology, Publisher : Baltimore : Williams & Wilkins, c1950-. Latest Publisher : Bethesda, MD : American Association of Immunologists, 2012, 189 (12), pp.5513-5517. ⟨10.4049/jimmunol.1201511⟩ Journal of Immunology, 2012, 189 (12), pp.5513-5517. ⟨10.4049/jimmunol.1201511⟩ |
| ISSN: | 1550-6606 0022-1767 |
| DOI: | 10.4049/jimmunol.1201511 |
| Popis: | Erratum in J Immunol. 2013 Feb 1;190(3):1381. Daëron, Marc [added].; International audience; mAb therapy for experimental metastatic melanoma relies on activating receptors for the Fc portion of IgG (FcγR). Opposing results on the respective contribution of mouse FcγRI, FcγRIII, and FcγRIV have been reported using the gp75-expressing B16 melanoma and the protective anti-gp75 mAb TA99. We analyzed the contribution of FcγRs to this therapy model using bioluminescent measurement of lung metastases loads, novel mouse strains, and anti-FcγR blocking mAbs. We found that the TA99 mAb-mediated effects in a combination therapy using cyclophosphamide relied on activating FcγRs. The combination therapy, however, was not more efficient than mAb therapy alone. We demonstrate that FcγRI and, unexpectedly, FcγRIII contributed to TA99 mAb therapeutic effects, whereas FcγRIV did not. Therefore, FcγRIII and FcγRI are, together, responsible for anti-gp75 mAb therapy of B16 lung metastases. Our finding that mouse FcγRIII contributes to Ab-induced tumor reduction correlates with clinical data on its human functional equivalent human FcγRIIIA (CD16A). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|